28 April 2010
The relative toxicity of compounds used as preservatives in vaccines and biologics
David A. GeierABCDEFG, Sarah K. JordanBE, Mark R. GeierABCDEFGMed Sci Monit 2010; 16(5): SR21-27 :: ID: 878526
Abstract
Background
In vaccines/biologics, preservatives are used to prevent microbial growth.
Material and Method
The present study examined: (1) the comparative toxicities of commonly used preservatives in US licensed vaccines to human neurons; and (2) the relative toxicity index of these compounds to human neurons in comparison to bacterial cells.
Results
Using human neuroblastoma cells, the relative cytotoxicity of the levels of the compounds commonly used as preservative in US licensed vaccines was found to be phenol <2-phenoxyethanol < benzethonium chloride < Thimerosal. The observed relative toxicity indices (human neuroblastoma cells/bacterial cells) were 2-phenoxyethanol (4.6-fold) < phenol (12.2-fold) < Thimerosal (>330-fold). In addition, for the compounds tested, except for 2-phenoxyethanol, the concentrations necessary to induce significant killing of bacterial cells were significantly higher than those routinely present in US licensed vaccine/biological preparations.
Conclusions
None of the compounds commonly used as preservatives in US licensed vaccine/biological preparations can be considered an ideal preservative, and their ability to fully comply with the requirements of the US Code of Federal Regulations (CFR) for preservatives is in doubt. Future formulations of US licensed vaccines/biologics should be produced in aseptic manufacturing plants as single dose preparations, eliminating the need for preservatives and an unnecessary risk to patients.
Keywords: Preservatives, Pharmaceutical - adverse effects, Cell Survival - drug effects, Escherichia coli - drug effects, Biological Products - adverse effects, Vaccines - adverse effects
Editorial
01 July 2026 : Editorial
Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development AcceleratesDOI: 10.12659/MSM.954627
Med Sci Monit 2026; 32:e954627
In Press
Laboratory Research
Evaluation of the Trueness and Precision of Cast, Milled-Cast, Milled, and 3D-Printed Post-and-Core Techniq...Med Sci Monit In Press; DOI: 10.12659/MSM.953491
Clinical Research
Outcomes After Minimally Invasive Intramedullary Nail Fixation and Locking Plate Fixation Among Patients Wi...Med Sci Monit In Press; DOI: 10.12659/MSM.952670
Laboratory Research
Influence of Scan Body Geometry, Implant Angulation, and Interimplant Distance on the Accuracy of Maxillary...Med Sci Monit In Press; DOI: 10.12659/MSM.953734
Clinical Research
Nasopharyngeal Carriage of Neisseria meningitidis in 181 Hajj and Umrah Pilgrims in Türkiye: Pre- and Post-...Med Sci Monit In Press; DOI: 10.12659/MSM.952640
Most Viewed Current Articles
17 Jan 2024 : Review article 14,176,304
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,758,119
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,466,183
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 708,842
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






